In the present article we conduct proof-of-principle studies to determine whether IAPs contribute to the apoptosis resistance of breast cancer cells to TNF-related apoptosis-inducing ligand (TRAIL) and ErbB antagonists. This evidence concerns the gene EGFR and breast carcinoma.